These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Seitz M; Wirthmüller U; Möller B; Villiger PM Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636 [TBL] [Abstract][Full Text] [Related]
51. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308 [TBL] [Abstract][Full Text] [Related]
52. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992 [TBL] [Abstract][Full Text] [Related]
53. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740 [TBL] [Abstract][Full Text] [Related]
54. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids. de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912 [TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185 [TBL] [Abstract][Full Text] [Related]
56. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA; Pincus T Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
58. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Bowes JD; Potter C; Gibbons LJ; Hyrich K; Plant D; Morgan AW; Wilson AG; Isaacs JD; Worthington J; Barton A; Pharmacogenet Genomics; 2009 Apr; 19(4):319-23. PubMed ID: 19262425 [TBL] [Abstract][Full Text] [Related]
59. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877 [TBL] [Abstract][Full Text] [Related]
60. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Iannone F; Tampoia M; Giannini M; Lopalco G; Cantarini L; Villalta CD; Galeazzi M; Lapadula G Clin Exp Rheumatol; 2016; 34(3):424-9. PubMed ID: 26885600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]